The Board of Directors of Gemabank (MOEX: GEMA) has decided to convene a General Shareholders' Meeting to consider increasing the authorized capital by placing additional shares via open subscription.
The parameters of the potential placement, including the number of shares and the terms of their placement, will be determined if the General Shareholders' Meeting adopts an appropriate resolution and will be disclosed in accordance with the procedures established by law.
The General Shareholders' Meeting is scheduled for April 7, 2026.
The proceeds from the additional capital raise are planned to be used to finance the implementation of the Company's strategic development plans.
Gemabank is a biotechnology company, part of the Artgen Biotech Group (MOEX: ABIO), specializing in private blood stem cells banking and the development of gene therapy treatments for blood and immune-related diseases.